Ovarian Cancer

In addition to a fear of cancer recurrence, patients said feeling isolated was also a challenge associated with having ovarian cancer.

Rates of next-generation sequencing (NGS) more than doubled once a nurse navigation program was implemented.

Outcomes for patients with this form of the disease are poor and treatment options are limited.

This interview with the lead investigator of the MIRASOL trial, which was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, will appear with coverage of ASCO in the upcoming issue of Evidence-Based Oncology.

Latina women at risk of hereditary breast and ovarian cancer are less likely to be referred for genetic counseling and testing.

Following safety reports of bleeding events after treatment with upifitamab rilsodotin among patients with platinum-sensitive ovarian cancer, the FDA places a partial clinical hold on enrollment for the UP-NEXT and UPGRADE-A trials.

The confirmatory trial showed limited side effects relative to physician's choice of chemotherapy.

The antibody drug conjugate received FDA approval in November 2022.

In addition to the drug approval, the FDA approved a companion diagnostic to be used to identify patients who are eligible to receive the treatment.

Patients with ovarian cancer who lived within 10 miles of Kansas’s only National Cancer Institute–designated cancer center, and those of a non-White race, were shown to have less of a survival advantage.

Whitney Goldsberry, MD, clinician at the University of Alabama at Birmingham Hospital and fellow at the UAB Division of Gynecologic Oncology, gives her insight into the future of PARP inhibitors in ovarian cancer treatment.

An investigation of 24 women from the United Kingdom’s PROTECTOR trial has revealed that their concerns toward cancer risk and menopause affect their choice of surgery as treatment for ovarian cancer.

Whitney Goldsberry, MD, fellow at the University of Alabama's Division of Gynecologic Oncology, discusses findings from her and colleagues' recent analysis of cost-sharing trends for PARP inhibitors in ovarian cancer treatment.

Researchers from MD Anderson Cancer Center found that laparoscopy cost more upfront but eliminated wasteful treatment decisions.

Recent results with adavosertib in ovarian cancer could signal future positive results, given the number of trials using the targeted therapy with the PARP inhibitor olaparib.

Lauren M. Corduck, who turned a diagnosis of ovarian cancer into a crusade to educate others with similar genetic mutations, died on December 24, 2020. She was 49.

Certain elderly women with ovarian cancer might benefit from aggressive treatment methods, a study recently published in Annals of Surgical Oncology found.

Panel testing for genetic variants linked to more cancers is cost-effective than just testing or BRCA1/2 mutations, says a clinical director for a women's health company.

Daniel F. Hayes, MD, offers definitions and an algorithm for clinicians to define clinical utility.

A study links the size of cysts associated with endometriosis with coexistent ovarian cancer.

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, describes the current indications for PARP inhibitors in ovarian cancer.

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, discusses the ovarian cancer patients most likely to respond well to PARP inhibition.

Bradley Monk, MD, FACOG, FACS, a professor at the University of Arizona, chronicles the regulatory changes in PARP inhibitors as they gain more indications in ovarian cancer.

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, shares his experience mitigating the potential side effects of PARP inhibitors in ovarian cancer treatment.

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, professor at the University of Arizona and Creighton University in Phoenix, discusses the reimbursement of PARP inhibitors in ovarian cancer.

A combination of pembrolizumab with bevacizumab and cyclophosphamide showed clinical activity and tolerability in patients with recurrent ovarian cancer, a small study found.

Kazia Therapeutics will report the full results at a future scientific meeting.

One patient had a complete response and the majority of patients achieved disease control at 12 weeks.

New findings in Journal of the National Cancer Institute contradict previous research indicating that assisted reproductive technology might lead to an increased risk of ovarian cancer.